Benzinga | Oct 28, 2020 08:27AM EDT

UBS Initiates Coverage On Alexion Pharmaceuticals with Neutral Rating, Announces Price Target of $133

UBS initiates coverage on Alexion Pharmaceuticals (NASDAQ:ALXN) with a Neutral rating and announces Price Target of $133.